| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Islets of Langerhans Transplantation | 22 | 2022 | 101 | 5.260 |
Why?
|
| Pancreatectomy | 26 | 2022 | 129 | 5.180 |
Why?
|
| Pancreatitis, Chronic | 21 | 2021 | 168 | 4.630 |
Why?
|
| Pancreatitis | 6 | 2022 | 279 | 1.630 |
Why?
|
| Islets of Langerhans | 8 | 2022 | 87 | 1.230 |
Why?
|
| Postoperative Complications | 11 | 2022 | 1615 | 1.110 |
Why?
|
| Transplantation, Autologous | 13 | 2021 | 145 | 1.030 |
Why?
|
| Pancreatic Diseases | 4 | 2016 | 66 | 1.020 |
Why?
|
| Pancreas | 5 | 2019 | 225 | 0.970 |
Why?
|
| Pancreatic Neoplasms | 6 | 2020 | 332 | 0.940 |
Why?
|
| Patient Selection | 5 | 2017 | 592 | 0.900 |
Why?
|
| Quality of Life | 7 | 2019 | 1515 | 0.830 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2022 | 63 | 0.770 |
Why?
|
| Treatment Outcome | 20 | 2021 | 7029 | 0.680 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2019 | 11 | 0.680 |
Why?
|
| Carbon Monoxide | 1 | 2019 | 58 | 0.680 |
Why?
|
| Drainage | 6 | 2019 | 133 | 0.670 |
Why?
|
| Abdominal Pain | 2 | 2010 | 97 | 0.670 |
Why?
|
| Pancreatic Fistula | 3 | 2022 | 23 | 0.620 |
Why?
|
| Gastroenterology | 1 | 2019 | 98 | 0.620 |
Why?
|
| Sphincter of Oddi Dysfunction | 2 | 2009 | 48 | 0.610 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 5 | 2019 | 348 | 0.610 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 565 | 0.600 |
Why?
|
| Pancreaticoduodenectomy | 4 | 2015 | 34 | 0.600 |
Why?
|
| Humans | 52 | 2022 | 68618 | 0.570 |
Why?
|
| Societies, Medical | 1 | 2019 | 403 | 0.570 |
Why?
|
| Adult | 27 | 2021 | 21403 | 0.560 |
Why?
|
| Male | 36 | 2022 | 37321 | 0.550 |
Why?
|
| Anastomosis, Surgical | 3 | 2015 | 104 | 0.550 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2019 | 2324 | 0.540 |
Why?
|
| Middle Aged | 26 | 2021 | 21147 | 0.530 |
Why?
|
| Retrospective Studies | 17 | 2022 | 7277 | 0.520 |
Why?
|
| Follow-Up Studies | 9 | 2017 | 3259 | 0.500 |
Why?
|
| Clinical Protocols | 1 | 2016 | 172 | 0.500 |
Why?
|
| Perioperative Care | 1 | 2016 | 100 | 0.500 |
Why?
|
| Female | 33 | 2022 | 38074 | 0.490 |
Why?
|
| Laparoscopy | 3 | 2011 | 237 | 0.490 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 772 | 0.480 |
Why?
|
| Diabetes Mellitus | 3 | 2021 | 694 | 0.480 |
Why?
|
| Common Bile Duct | 2 | 2011 | 22 | 0.470 |
Why?
|
| Insulin | 5 | 2019 | 619 | 0.450 |
Why?
|
| Laparotomy | 2 | 2010 | 65 | 0.440 |
Why?
|
| Length of Stay | 7 | 2019 | 780 | 0.440 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 475 | 0.430 |
Why?
|
| Pain, Intractable | 2 | 2013 | 28 | 0.420 |
Why?
|
| Sphincterotomy, Transduodenal | 3 | 2013 | 24 | 0.420 |
Why?
|
| Psychometrics | 1 | 2015 | 514 | 0.410 |
Why?
|
| Choledochostomy | 2 | 2011 | 10 | 0.400 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2011 | 6 | 0.400 |
Why?
|
| Intestinal Neoplasms | 1 | 2011 | 30 | 0.400 |
Why?
|
| Sacrococcygeal Region | 1 | 2011 | 4 | 0.400 |
Why?
|
| Incidental Findings | 1 | 2011 | 42 | 0.390 |
Why?
|
| Rectal Diseases | 1 | 2011 | 13 | 0.390 |
Why?
|
| Hamartoma | 1 | 2011 | 24 | 0.390 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 64 | 0.390 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 2011 | 14 | 0.380 |
Why?
|
| Gastric Bypass | 2 | 2009 | 83 | 0.380 |
Why?
|
| Cysts | 1 | 2011 | 70 | 0.370 |
Why?
|
| Schistosomiasis | 1 | 2010 | 6 | 0.370 |
Why?
|
| Diagnosis, Differential | 5 | 2011 | 1140 | 0.370 |
Why?
|
| Reoperation | 6 | 2013 | 467 | 0.360 |
Why?
|
| Wounds, Penetrating | 1 | 2010 | 45 | 0.350 |
Why?
|
| Risk Management | 1 | 2010 | 37 | 0.350 |
Why?
|
| Stomach Diseases | 1 | 2010 | 22 | 0.350 |
Why?
|
| Warfare | 1 | 2010 | 58 | 0.350 |
Why?
|
| Stomach | 1 | 2010 | 80 | 0.350 |
Why?
|
| Abdominal Injuries | 1 | 2010 | 60 | 0.350 |
Why?
|
| Obesity, Morbid | 2 | 2009 | 172 | 0.350 |
Why?
|
| Sarcoidosis | 1 | 2010 | 77 | 0.350 |
Why?
|
| Emphysema | 1 | 2010 | 32 | 0.350 |
Why?
|
| Analgesics, Opioid | 2 | 2012 | 498 | 0.340 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2010 | 110 | 0.340 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 129 | 0.330 |
Why?
|
| Intestinal Perforation | 1 | 2009 | 35 | 0.330 |
Why?
|
| Kidney Neoplasms | 1 | 2010 | 206 | 0.320 |
Why?
|
| Digestive System Abnormalities | 1 | 2008 | 7 | 0.310 |
Why?
|
| Cholecystectomy | 2 | 2018 | 79 | 0.300 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 581 | 0.260 |
Why?
|
| Cytokines | 3 | 2019 | 866 | 0.260 |
Why?
|
| Biopsy | 3 | 2011 | 540 | 0.240 |
Why?
|
| Aged | 11 | 2020 | 14862 | 0.240 |
Why?
|
| Gallstones | 2 | 2018 | 58 | 0.230 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 2800 | 0.230 |
Why?
|
| Copper Radioisotopes | 1 | 2023 | 5 | 0.220 |
Why?
|
| Cyclooctanes | 1 | 2023 | 5 | 0.220 |
Why?
|
| Click Chemistry | 1 | 2023 | 7 | 0.220 |
Why?
|
| Elective Surgical Procedures | 2 | 2016 | 95 | 0.210 |
Why?
|
| Molecular Imaging | 1 | 2023 | 45 | 0.210 |
Why?
|
| Time Factors | 5 | 2019 | 4655 | 0.200 |
Why?
|
| Antibodies | 1 | 2023 | 241 | 0.200 |
Why?
|
| Positron-Emission Tomography | 1 | 2023 | 160 | 0.200 |
Why?
|
| Receptors, Interleukin-8A | 1 | 2021 | 1 | 0.200 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2021 | 9 | 0.200 |
Why?
|
| Amyloid beta-Peptides | 1 | 2023 | 191 | 0.190 |
Why?
|
| Young Adult | 4 | 2015 | 5717 | 0.190 |
Why?
|
| Bile Ducts | 1 | 2021 | 59 | 0.180 |
Why?
|
| Hepatectomy | 1 | 2020 | 58 | 0.180 |
Why?
|
| Graft Survival | 3 | 2022 | 465 | 0.180 |
Why?
|
| Travel | 1 | 2020 | 38 | 0.180 |
Why?
|
| Chemokines, CC | 1 | 2019 | 18 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2022 | 529 | 0.180 |
Why?
|
| Risk Assessment | 3 | 2011 | 2007 | 0.180 |
Why?
|
| Glucose Tolerance Test | 1 | 2019 | 75 | 0.170 |
Why?
|
| Glucose Intolerance | 1 | 2019 | 36 | 0.170 |
Why?
|
| Self Expandable Metallic Stents | 1 | 2019 | 14 | 0.170 |
Why?
|
| Chemokine CXCL12 | 1 | 2019 | 51 | 0.170 |
Why?
|
| Risk Factors | 5 | 2022 | 5731 | 0.170 |
Why?
|
| Debridement | 1 | 2019 | 55 | 0.170 |
Why?
|
| Survival Rate | 2 | 2020 | 1056 | 0.160 |
Why?
|
| Adolescent | 3 | 2019 | 8912 | 0.160 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 163 | 0.160 |
Why?
|
| DNA Methylation | 1 | 2019 | 193 | 0.160 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 1174 | 0.150 |
Why?
|
| Anxiety | 1 | 2021 | 422 | 0.150 |
Why?
|
| Cell Line, Tumor | 1 | 2023 | 1851 | 0.150 |
Why?
|
| Enteral Nutrition | 1 | 2019 | 157 | 0.150 |
Why?
|
| Cholangitis | 1 | 2017 | 15 | 0.150 |
Why?
|
| Blood Glucose | 2 | 2017 | 631 | 0.150 |
Why?
|
| United States | 6 | 2019 | 7367 | 0.150 |
Why?
|
| Mice | 4 | 2023 | 8474 | 0.150 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2017 | 79 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 334 | 0.140 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2017 | 48 | 0.140 |
Why?
|
| Insulin-Secreting Cells | 1 | 2017 | 41 | 0.140 |
Why?
|
| Prospective Studies | 4 | 2021 | 3705 | 0.140 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2017 | 61 | 0.140 |
Why?
|
| Adipose Tissue | 1 | 2017 | 221 | 0.130 |
Why?
|
| Cell-Penetrating Peptides | 1 | 2016 | 8 | 0.130 |
Why?
|
| Endoscopy | 1 | 2019 | 464 | 0.130 |
Why?
|
| Paraganglioma | 1 | 2015 | 8 | 0.130 |
Why?
|
| Cell Membrane Permeability | 1 | 2016 | 59 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2021 | 447 | 0.130 |
Why?
|
| Stem Cells | 1 | 2017 | 248 | 0.130 |
Why?
|
| Ampulla of Vater | 1 | 2015 | 34 | 0.130 |
Why?
|
| Allografts | 1 | 2016 | 63 | 0.130 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 35 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 931 | 0.130 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 114 | 0.130 |
Why?
|
| Animals | 6 | 2023 | 20881 | 0.130 |
Why?
|
| Hospital Costs | 1 | 2016 | 117 | 0.120 |
Why?
|
| Lymphatic Metastasis | 1 | 2015 | 274 | 0.120 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2017 | 195 | 0.120 |
Why?
|
| Gastrostomy | 1 | 2015 | 110 | 0.120 |
Why?
|
| Depression | 1 | 2021 | 943 | 0.120 |
Why?
|
| Postoperative Period | 1 | 2015 | 238 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2021 | 2358 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2017 | 1342 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2011 | 2223 | 0.110 |
Why?
|
| Apoptosis | 2 | 2017 | 1641 | 0.110 |
Why?
|
| Smoking | 1 | 2021 | 1452 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 4 | 2022 | 2791 | 0.110 |
Why?
|
| Health Services | 1 | 2013 | 87 | 0.110 |
Why?
|
| Alcoholism | 1 | 2021 | 1109 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2016 | 506 | 0.100 |
Why?
|
| Endosonography | 2 | 2010 | 177 | 0.100 |
Why?
|
| Bacterial Infections | 1 | 2013 | 163 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 235 | 0.100 |
Why?
|
| Interprofessional Relations | 1 | 2013 | 188 | 0.100 |
Why?
|
| Pain Management | 1 | 2013 | 186 | 0.100 |
Why?
|
| Macrophages | 3 | 2022 | 647 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 191 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2011 | 75 | 0.090 |
Why?
|
| Hospitals, Low-Volume | 2 | 2020 | 12 | 0.090 |
Why?
|
| Hospitals, High-Volume | 2 | 2020 | 18 | 0.090 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2010 | 7 | 0.090 |
Why?
|
| Colonoscopy | 1 | 2011 | 156 | 0.090 |
Why?
|
| Vipoma | 1 | 2010 | 2 | 0.090 |
Why?
|
| Gastrinoma | 1 | 2010 | 2 | 0.090 |
Why?
|
| Somatostatinoma | 1 | 2010 | 3 | 0.090 |
Why?
|
| Splenectomy | 1 | 2010 | 40 | 0.090 |
Why?
|
| Insulinoma | 1 | 2010 | 4 | 0.090 |
Why?
|
| Glucagonoma | 1 | 2010 | 3 | 0.090 |
Why?
|
| Jejunum | 1 | 2010 | 26 | 0.090 |
Why?
|
| Blast Injuries | 1 | 2010 | 15 | 0.090 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2010 | 13 | 0.090 |
Why?
|
| Multiple Trauma | 1 | 2010 | 50 | 0.090 |
Why?
|
| Gastroscopy | 1 | 2010 | 45 | 0.090 |
Why?
|
| Gastrectomy | 1 | 2009 | 24 | 0.090 |
Why?
|
| Injury Severity Score | 1 | 2010 | 204 | 0.090 |
Why?
|
| Peptic Ulcer | 1 | 2009 | 37 | 0.080 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 236 | 0.080 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 36 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 349 | 0.080 |
Why?
|
| Angiography | 1 | 2010 | 194 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2011 | 652 | 0.080 |
Why?
|
| Cholestasis | 1 | 2009 | 90 | 0.080 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 186 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2010 | 453 | 0.080 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2007 | 17 | 0.080 |
Why?
|
| Octreotide | 1 | 2007 | 21 | 0.080 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2007 | 24 | 0.080 |
Why?
|
| Nutritional Support | 1 | 2007 | 22 | 0.080 |
Why?
|
| Ascites | 1 | 2007 | 38 | 0.080 |
Why?
|
| Gastrointestinal Agents | 1 | 2007 | 51 | 0.070 |
Why?
|
| Pleural Effusion | 1 | 2007 | 74 | 0.070 |
Why?
|
| Child | 2 | 2015 | 6405 | 0.070 |
Why?
|
| Recurrence | 2 | 2021 | 948 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2020 | 622 | 0.070 |
Why?
|
| Wounds and Injuries | 1 | 2010 | 334 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2016 | 2689 | 0.070 |
Why?
|
| Logistic Models | 2 | 2021 | 1420 | 0.070 |
Why?
|
| Cell Death | 2 | 2017 | 329 | 0.060 |
Why?
|
| Transplantation, Homologous | 2 | 2017 | 242 | 0.060 |
Why?
|
| Prognosis | 1 | 2010 | 2093 | 0.060 |
Why?
|
| United States Food and Drug Administration | 2 | 2015 | 131 | 0.060 |
Why?
|
| Stents | 1 | 2008 | 657 | 0.060 |
Why?
|
| C-Peptide | 1 | 2021 | 23 | 0.050 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2021 | 4 | 0.050 |
Why?
|
| Registries | 2 | 2015 | 733 | 0.050 |
Why?
|
| Academies and Institutes | 1 | 2020 | 31 | 0.050 |
Why?
|
| Injections | 1 | 2021 | 119 | 0.050 |
Why?
|
| Solutions | 1 | 2021 | 115 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2021 | 109 | 0.040 |
Why?
|
| Inflammation | 2 | 2017 | 1030 | 0.040 |
Why?
|
| Acute Disease | 1 | 2021 | 658 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 80 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 96 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 792 | 0.040 |
Why?
|
| Behavior, Animal | 1 | 2021 | 470 | 0.040 |
Why?
|
| Tissue Survival | 1 | 2017 | 22 | 0.040 |
Why?
|
| Multiple Chronic Conditions | 1 | 2017 | 9 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2017 | 31 | 0.040 |
Why?
|
| Choledocholithiasis | 1 | 2017 | 14 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 42 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2017 | 147 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 58 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2017 | 49 | 0.040 |
Why?
|
| Propensity Score | 1 | 2017 | 117 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 138 | 0.040 |
Why?
|
| Antithrombin III | 1 | 2017 | 23 | 0.040 |
Why?
|
| Thromboplastin | 1 | 2017 | 21 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 951 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2017 | 238 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 110 | 0.040 |
Why?
|
| South Carolina | 2 | 2013 | 2752 | 0.040 |
Why?
|
| Peptide Hydrolases | 1 | 2017 | 82 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 122 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2017 | 87 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2017 | 140 | 0.030 |
Why?
|
| Histocompatibility Antigens | 1 | 2016 | 12 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1553 | 0.030 |
Why?
|
| RAW 264.7 Cells | 1 | 2016 | 42 | 0.030 |
Why?
|
| Cytoprotection | 1 | 2016 | 39 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 244 | 0.030 |
Why?
|
| Protein Domains | 1 | 2016 | 74 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2016 | 92 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 498 | 0.030 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2014 | 4 | 0.030 |
Why?
|
| Etanercept | 1 | 2014 | 12 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2014 | 32 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2017 | 432 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 532 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2015 | 123 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 626 | 0.030 |
Why?
|
| Autografts | 1 | 2013 | 22 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2017 | 1200 | 0.030 |
Why?
|
| Diagnosis-Related Groups | 1 | 2013 | 28 | 0.030 |
Why?
|
| Heparin | 1 | 2014 | 205 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 2550 | 0.030 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 62 | 0.030 |
Why?
|
| Research | 1 | 2014 | 214 | 0.030 |
Why?
|
| Pancreaticojejunostomy | 1 | 2013 | 21 | 0.030 |
Why?
|
| Chronic Pain | 1 | 2015 | 110 | 0.030 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2013 | 49 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 234 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 481 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2014 | 356 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 281 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2015 | 310 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2013 | 267 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 514 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2014 | 413 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1293 | 0.020 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2008 | 15 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2010 | 275 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 1026 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2008 | 1330 | 0.010 |
Why?
|